

# GIST AVANZATI: il valore della gestione multidisciplinare del Paziente

## Il ruolo del chirurgo

*Prof.ssa Maria Bencivenga*

*Chirurgia generale e dell'esofago e dello stomaco*

*Ospedale Borgo Trento – Verona*

# Il ruolo del chirurgo

SNODO DECISIONALE - chirurgia della malattia **in risposta**

→ **Complete excision of residual metastatic disease has been shown to be associated with a good prognosis, provided the patient is responding to Imatinib.**





## SPECIAL ARTICLE

**Gastrointestinal stromal tumours: ESMO—EURACAN—GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>**



# Il ruolo del chirurgo







Available at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.ejcancer.com](http://www.ejcancer.com)



## Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China



Small cohort of patients but...




Fig. 1. Flow chart diagram that accounts for all patients in COMVIA.

# Il ruolo del chirurgo

## SNODO DECISIONALE - chirurgia della malattia in progressione focale

→ Surgical excision of progressing disease should be considered for an individual patient with limited progression, while continuing imatinib



### SPECIAL ARTICLE

Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up



# Il ruolo del chirurgo

## SNODO DECISIONALE - chirurgia della malattia **in progressione focale**

→ **Surgical excision of progressing disease has not been rewarding in published series, but surgery of limited progression, such as the ‘nodule within a mass’, has been associated with a progression-free interval in the same range as for second-line treatment with sunitinib.**



### SPECIAL ARTICLE

**Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up**

CONSENSUS STATEMENT

OPEN



Clinical Studies

## Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines

Ian Judson <sup>1✉</sup>, Robin L. Jones <sup>2</sup>, Newton A. C. S. Wong<sup>3</sup>, Palma Dileo<sup>4</sup>, Ramesh Bulusu<sup>5</sup>, Myles Smith<sup>2</sup> and Max Almond<sup>6</sup>

© The Author(s) 2024

Gastric Cancer (2007) 10: 145–152  
DOI 10.1007/s10120-007-0425-8

*Original article*



## **Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients**

SALAH-EDDIN AL-BATRAN<sup>1</sup>, JOERG THOMAS HARTMANN<sup>2</sup>, FLORIAN HEIDEL<sup>3</sup>, JAN STOEHLMACHER<sup>4</sup>, EVA WARDELMANN<sup>5</sup>, CLAUDIUS DECHOW<sup>6</sup>, MARKUS DÜX<sup>6</sup>, JACOB ROBERT IZBICKI<sup>4</sup>, THOMAS KRAUS<sup>7</sup>, THOMAS FISCHER<sup>3</sup>, and ELKE JÄGER<sup>1</sup>



# Il ruolo del chirurgo

## SNODO DECISIONALE - chirurgia della malattia **metastatica**



Cancer Therapy

### **Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib<sup>†</sup>**

Sebastian Bauer ✉, Jörg Thomas Hartmann, Maike de Wit, Hauke Lang, Florian Grabellus, Gerald Antoch, Wolfgang Niebel, Jochen Erhard, Peter Ebeling, Matthias Zeth ... [See all authors](#) ✓

First published: 16 August 2005 | <https://doi.org/10.1002/ijc.21164> | Citations: 130

90 patients with metastatic GIST in with imatinib.

12 pt with mostly recurrent and extensive disease to be considered for **resection of residual disease**.

In 11 of these patients, complete resection could be achieved BUT viable tumor cells were found!

→ **Imatinib is unlikely to induce pathological complete responses.**



→ **Surgical approach should be considered for all patients with metastatic GIST.**



# Il ruolo del chirurgo

## SNODO DECISIONALE - chirurgia della malattia metastatica

OPEN

### Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib

20 January 2016

4 February 2016

07 March 2016

Xiaodong Gao<sup>1,2,\*</sup>, Anwei Xue<sup>1,2,\*</sup>, Yong Fang<sup>1,2</sup>, Ping Shu<sup>1,2</sup>, Jiaqian Ling<sup>1,2</sup>, Jing Qin<sup>1,2</sup>, Yingyong Hou<sup>3</sup>, Kuntang Shen<sup>1,2</sup>, Yihong Sun<sup>1,2</sup> & Xinyu Qin<sup>1,2</sup>

# BUT...

Although surgery may be useful for certain patients with metastatic or recurrent GIST resistant to TKIs, currently there is insufficient evidence to show its usefulness.



English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology

Seiichi Hirota<sup>1</sup> · Ukihide Tateishi<sup>2</sup> · Yuji Nakamoto<sup>3</sup> · Hidetaka Yamamoto<sup>4</sup> · Shinji Sakurai<sup>5</sup> · Hirotohi Kikuchi<sup>6</sup> · Tatsuo Kanda<sup>7</sup> · Yukinori Kurokawa<sup>8</sup> · Haruhiko Cho<sup>9</sup> · Toshiro Nishida<sup>10</sup> · Akira Sawaki<sup>11</sup> · Masato Ozaka<sup>12</sup> · Yoshito Komatsu<sup>13</sup> · Yoichi Naito<sup>14</sup> · Yoshitaka Honma<sup>15</sup> · Fumiaki Takahashi<sup>16</sup> · Hironobu Hashimoto<sup>17</sup> · Midori Udo<sup>18</sup> · Minako Araki<sup>19</sup> · Sumito Nishidate<sup>20</sup> · Members of the Systematic Review Team of the Present Guidelines

Received: 27 December 2023 / Accepted: 12 February 2024 / Published online: 13 April 2024  
© The Author(s) 2024



# Il ruolo del chirurgo

SNODO DECISIONALE – trattamento locale della malattia **metastatica**

**BUT...** Cytoreductive surgery aiming at R0/R1 disease following initial response to imatinib is associated with improved long-term survival.

✘ **Debulking surgery, does not seem to prolong survival.**

✘ **HIPEC**

**Selected patients may undergo cytoreductive surgery after initial response to imatinib and if the metastatic disease is deemed resectable.**

**Avoid mutilating procedures and maintain imatinib afterward!!**

**2023 GEIS Guidelines for gastrointestinal stromal tumors**

César Serrano, Javier Martín-Broto, José Manuel Asencio-Pascual, José Antonio López-Guerrero, Jordi Rubió-Casadevall, Silvia Bagué, Xavier García-del-Muro, Juan Ángel Fernández-Hernández, Luís Herrero, Antonio López-Pousa, Andrés Poveda and Virginia Martínez-Marín, On behalf of GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research)

*The Adv Med Oncol*

2023, Vol. 15: 1–18

DOI: 10.1177/  
17588359231192388

© The Author(s), 2023.  
Article reuse guidelines:  
[sagepub.com/journals-  
permissions](https://sagepub.com/journals-permissions)



Thank  
you

